Sign In to Follow Application
View All Documents & Correspondence

A Composition Comprising Of Glycyrrhiza Glabra Extract, And Vitex Negundo Extract And Uses Thereof

Abstract: The present disclosure provides a composition comprising of Glycyrrhiza glabra extract and Vitex negundo extract that is useful in pain and/or inflammation management. Also provided is a method of monitoring of pain and/or inflammation at site by measuring fluorescence of said composition.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
23 March 2015
Publication Number
41/2016
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
lsmds@lakshmisri.com
Parent Application
Patent Number
Legal Status
Grant Date
2023-09-26
Renewal Date

Applicants

ITC LIMITED
ITC LIFE SCIENCES AND TECHNOLOGY CENTRE #3, 1st Main, Peenya Industrial Area, Phase 1, Bangalore 560 058, India

Inventors

1. DSOUZA, Avin
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India
2. NARAYANPERUMAL, Jeyaparthasarathy
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India
3. DAS, Shibendu
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India
4. MIRIYALA, Amarnath
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India
5. MURALI, Deepa
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India
6. GOPAL, Ganesh
ITC Life Sciences and Technology Centre, #3, 1st Main, Peenya Industrial Area, Phase I, Bangalore 560 058, India

Specification

CLIAMS:1. A composition comprising of:
a. Glycyrrhiza glabra extract; and
b. Vitex negundo extract,
wherein said composition inhibits pain.
2. The composition as claimed in claim 1, wherein Glycyrrhiza glabra extract to Vitex negundo extract w/w ratio in said composition is 1:0.2-1:0.8.
3. A composition comprising of:
a. Glycyrrhiza glabra extract; and
b. Vitex negundo extract,
wherein said composition inhibits inflammation.
4. The composition as claimed in claim 3, wherein Glycyrrhiza glabra extract to Vitex negundo extract w/w ratio in said composition is 1:0.2.
5. The composition as claimed in any of the claims 1-4, wherein said composition has auto-fluorescence properties.
6. A method of inhibiting pain, said method comprising of:
a. obtaining a composition as claimed in any of the claims 1-2, or 5, and
b. contacting said composition with site of pain,
wherein said method inhibits pain.
7. A method of inhibiting inflammation, said method comprising of:
a. obtaining a composition as claimed in any of the claims 3-5; and
b. contacting said composition with site of inflammation,
wherein said method inhibits inflammation.
8. An adhesive patch for topical application for management of pain, said adhesive patch comprising of a composition as claimed in any of the claims 1-2, or 5.
9. An adhesive patch for topical application for management of inflammation, said adhesive patch comprising of a composition as claimed in any of the claims 3-5.
10. The adhesive patch as claimed in any of the claims 8-9, further comprising of suitable carriers, diluents, and excipients
11. A method of preparing an adhesive patch as claimed in any of the claims 8-10.
12. A method of monitoring pain management, said method comprising of:
a. obtaining a composition as claimed in any of the claims 1-2, or 5; or an adhesive patch as claimed in any of the claims 8, or 10;
b. contacting said composition or adhesive patch with site of pain; and
c. monitoring fluorescence activity of said composition or adhesive patch,
wherein increase in fluorescence of said composition or adhesive patch is indicative of effective pain management.
13. A method of monitoring inflammation management, said method comprising of:
a. obtaining a composition as claimed in any of the claims 3-5; or an adhesive patch as claimed in any of the claims 9-10;
b. contacting said composition or adhesive patch with site of inflammation; and
c. monitoring fluorescence activity of said composition or adhesive patch,
wherein increase in fluorescence of said composition or adhesive patch is indicative of effective inflammation management.
14. A composition as claimed in any of the claims 1-2, or 5; or an adhesive patch as claimed in any of the claims 8, or 10 for use in pain management.

15. A composition as claimed in any of the claims 3-5; or an adhesive patch as claimed in any of the claims 9-10 for use in inflammation management.
,TagSPECI:As Attached

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 1475-CHE-2015-IntimationOfGrant26-09-2023.pdf 2023-09-26
1 PD015621IN-SC SPEC FOR FILING.pdf 2015-03-28
2 1475-CHE-2015-PatentCertificate26-09-2023.pdf 2023-09-26
2 PD015621IN-SC FORM 5.pdf 2015-03-28
3 PD015621IN-SC FORM 3.pdf 2015-03-28
3 1475-CHE-2015-Written submissions and relevant documents [05-12-2022(online)].pdf 2022-12-05
4 PD015621IN-SC FIGURES FOR FILING.pdf 2015-03-28
4 1475-CHE-2015-Correspondence to notify the Controller [18-11-2022(online)].pdf 2022-11-18
5 1475-CHE-2015-US(14)-ExtendedHearingNotice-(HearingDate-21-11-2022).pdf 2022-10-28
5 1475-CHE-2015 POWER OF ATTORNEY 24-04-2015.pdf 2015-04-24
6 1475-CHE-2015-Correspondence to notify the Controller [06-09-2022(online)].pdf 2022-09-06
6 1475-CHE-2015 FORM-1 24-04-2015.pdf 2015-04-24
7 1475-CHE-2015-Correspondence to notify the Controller [31-08-2022(online)].pdf 2022-08-31
7 1475-CHE-2015 CORRESPONDENCE OTHERS 24-04-2015.pdf 2015-04-24
8 1475-CHE-2015-US(14)-HearingNotice-(HearingDate-02-09-2022).pdf 2022-08-01
8 1475-CHE-2015-FORM 18 [01-02-2019(online)].pdf 2019-02-01
9 1475-CHE-2015-CLAIMS [19-11-2021(online)].pdf 2021-11-19
9 1475-CHE-2015-FER.pdf 2021-10-17
10 1475-CHE-2015-FER_SER_REPLY [19-11-2021(online)].pdf 2021-11-19
11 1475-CHE-2015-CLAIMS [19-11-2021(online)].pdf 2021-11-19
11 1475-CHE-2015-FER.pdf 2021-10-17
12 1475-CHE-2015-FORM 18 [01-02-2019(online)].pdf 2019-02-01
12 1475-CHE-2015-US(14)-HearingNotice-(HearingDate-02-09-2022).pdf 2022-08-01
13 1475-CHE-2015 CORRESPONDENCE OTHERS 24-04-2015.pdf 2015-04-24
13 1475-CHE-2015-Correspondence to notify the Controller [31-08-2022(online)].pdf 2022-08-31
14 1475-CHE-2015 FORM-1 24-04-2015.pdf 2015-04-24
14 1475-CHE-2015-Correspondence to notify the Controller [06-09-2022(online)].pdf 2022-09-06
15 1475-CHE-2015 POWER OF ATTORNEY 24-04-2015.pdf 2015-04-24
15 1475-CHE-2015-US(14)-ExtendedHearingNotice-(HearingDate-21-11-2022).pdf 2022-10-28
16 1475-CHE-2015-Correspondence to notify the Controller [18-11-2022(online)].pdf 2022-11-18
16 PD015621IN-SC FIGURES FOR FILING.pdf 2015-03-28
17 1475-CHE-2015-Written submissions and relevant documents [05-12-2022(online)].pdf 2022-12-05
17 PD015621IN-SC FORM 3.pdf 2015-03-28
18 1475-CHE-2015-PatentCertificate26-09-2023.pdf 2023-09-26
18 PD015621IN-SC FORM 5.pdf 2015-03-28
19 PD015621IN-SC SPEC FOR FILING.pdf 2015-03-28
19 1475-CHE-2015-IntimationOfGrant26-09-2023.pdf 2023-09-26

Search Strategy

1 2021-05-0712-50-23E_07-05-2021.pdf

ERegister / Renewals

3rd: 28 Nov 2023

From 23/03/2017 - To 23/03/2018

4th: 28 Nov 2023

From 23/03/2018 - To 23/03/2019

5th: 28 Nov 2023

From 23/03/2019 - To 23/03/2020

6th: 28 Nov 2023

From 23/03/2020 - To 23/03/2021

7th: 28 Nov 2023

From 23/03/2021 - To 23/03/2022

8th: 28 Nov 2023

From 23/03/2022 - To 23/03/2023

9th: 28 Nov 2023

From 23/03/2023 - To 23/03/2024

10th: 28 Nov 2023

From 23/03/2024 - To 23/03/2025

11th: 14 Feb 2025

From 23/03/2025 - To 23/03/2026